A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis

Exclusion Criteria

• •1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
• •2. Subject is currently enrolled in an investigational drug or device study.
• •3. Subject has used an investigational drug or investigational device treatment within 30 days prior to Visit 2/Baseline.
• •4. Subject has active cutaneous bacterial or viral infection in any treatment area (clinically infected hand dermatitis) at Visit 2/Baseline.
• •5. Subject has used any of the following therapies within 30 days prior to Visit 2/Baseline:
• •* Systemic corticosteroids (oral and injectable \[intravenous and intramuscular\]) (Intranasal and Inhalational steroids are allowed if use is kept constant during the study)
• •* UVA/UVB therapy
• •* PUVA (psoralen plus ultraviolet A) therapy
• •* Immunomodulators or immunosuppressive therapies
• •* Interferon
• •* Cytotoxic drugs (e.g., methotrexate, cyclophosphamide, azathioprine)
• •* Oral retinoids
• •6. Subject has used any of the following therapies within 14 days prior to Visit 2/Baseline:
• •* Systemic antibiotics
• •* Topical calcipotriene or other topical vitamin D preparations
• •7. Subject has used any of the following therapies within 7 days prior to Visit 2/Baseline: • Topical and oral antihistamines
• •* Topical antibiotics
• •* Topical corticosteroids
• •* Topical antifungals
• •8. Subject has a history of sensitivity to any of the ingredients in the investigational product
• •9. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.